BofA upgraded Alignment Healthcare to Buy from Neutral with a price target of $11, up from $7.75. The company is signaling a pivot to focusing on margin over growth for the first time since the IPO and the firm sees improving visibility into margin progression, the analyst tells investors. Alignment is in the “unique position where the bulk of its competitors are facing sizable multi-year headwinds,” giving the company cover to cut benefits and improve profitability without losing share, the analyst contends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare to Present at William Blair’s 44th Annual Growth Stock Conference
- Piper Sandler upgrades Alignment Healthcare to Overweight on strong resuts
- Alignment Healthcare upgraded to Overweight from Neutral at Piper Sandler
- Alignment Healthcare price target raised to $7 from $6 at Stephens
- Alignment Healthcare reports Q1 EPS (25c), consensus (22c)